Buffalo biopharma firm Athenex files for bankruptcy, will pursue sale ...
2024-10-02 06:25For Athenex, it's been one issue after another since March 2021 when a drug it was developing to treat breast cancer was set back by years after federal regulators raised questions about the late ...
Athenex, Inc. 與貸方達成協議,推動快速銷售進程
公司預計將在 2023 年 7 月 1 日結束此快速銷售進程,而第 11 章破產案將持續至解決所有索賠問題為止。. Athenex 亦已與其貸方就同意使用現金抵押物 ...
Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets, the company said in a statement. The Buffalo, New York-based company has listed ...
Athenex Announces Entry into Agreement to Sell its China - GlobeNewswire
About Athenex, Inc. Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next ...
Buffalo Billion's Athenex files bankruptcy | News 4 Buffalo - WIVB News 4
The bankruptcy filing on May 14 estimates Athenex has between 200 and 999 creditors. The company reported debts exceeding $228 million and assets worth $204 million. Athenex lists Fort Schuyler ...
Athenex assets sold in bankruptcy auction; top executives dismissed
A Hong Kong-based company, C-Mer Specialty Group Limited, was the highest bidder for Athenex R&D's assets used in small molecule or Orascovery business, according to the SEC. The company paid $2 ...
Athenex files for bankruptcy, seeks buyer for cell therapy unit
Athenex has run out of road. With programs stumbling and cash running out, the drug developer has filed for bankruptcy and begun seeking buyers for its three businesses.. New York-based Athenex ...
Buffalo Billion project Athenex files for Chapter 11 bankruptcy
Things continued to get worse for the Buffalo-based company. Athenex, Inc., biopharmaceutical company, announced Monday that they filed Chapter 11 in U.S. Bankruptcy Court. They say they have an ...
Athenex, Inc. Reaches Agreement With Lenders to Pursue - GlobeNewswire
Dr. Johnson Lau, Chief Executive Officer of Athenex, on behalf of the management team and the Athenex Board of Directors, said, "Throughout our history, we have sought to become a leader in ...
5月15日丨Athenex(ATNX.US)盤前暴跌超50%報0.553美元。公司週日表示,該公司及其某些子公司已經向美國德克薩斯州南區破產法院提交了自願破產程序 ...
In the United States Bankruptcy Court for The Southern District of ...
The location of Athenex, Inc.'s principal place of business and the Debtors' service address in these Chapter 11 Cases is 1001 Main Street, Suite 600, Buffalo, NY 14203. Case 23-90295 Document 162 Filed in TXSB on 06/02/23 Page 1 of 11. 2 DOCS_LA:349334.4 14039/002
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ...
The Company anticipates concluding the expedited sales process by July 1, 2023, with the Chapter 11 cases continuing thereafter to resolve claims. Athenex has also reached an agreement with its ...
Athenex, Inc. 與貸方達成協議,推動快速銷售進程 - 產經商業 - 台灣產經新聞網 - Taiwan Business News
台灣產經新聞網 產經商業訊息(文章來源:Notified):Athenex, Inc. 與貸方達成協議,推動快速銷售進程 為更好地推進事務發展,公司自願申請第 11 章破產程序 公司擁有足夠的資源支援 Athenex Pharma Solutions 的營運,並在此進程期間,完成 APD 客戶訂單 紐約布法羅, May 15, 2023 ( ...
Athenex faces patient death, FDA hold for phase 1 trial - Fierce Biotech
Since closing Friday, the company's stock has plunged 18%, however, falling from $1.76 to $1.45 at midday today. Athenex clinical hold Cell & Gene Therapy neuroblastoma Biotech. After a ...
Athenex, Inc. 與貸方達成協議,推動快速銷售進程 | 新頭條-TheHubNews
為了此進程更加順利,Athenex 及其某些子公司已根據《美國破產法》第 11 章,在美國德克薩斯州南區破產法院自願申請破產程序。如此,公司將有序地出售其資產並逐步關閉 Athenex 平台,同時為權益關係者爭取最大的價值。
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies ...
Athenex Announces a Reverse Stock Split - Yahoo Finance
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies ...
Athenex自願申請破產保護,股價暴跌 港美股資訊 | 華盛通
Athenex自願申請破產保護,股價暴跌. 周日,Athenex Inc. (納斯達克股票代碼:ATNX)及其某些子公司自願申請破產保護。. Athenex在一份聲明中表示,該公司與貸款人達成協議,將加快出售其資產的進程。. 路透社援引提交給德克薩斯州南區美國破產法院的一份文件報道 ...
Athenex's bankruptcy won't be the end of drug development in Buffalo ...
Athenex's Oraxol made it past the highest risks. Phase I of clinical trials is really the first trial on humans, Dunbar said, while Phase II further explores testing for the right dosing, safety ...
Athenex, Inc. 與貸方達成協議,推動快速銷售進程 | 蕃新聞
公司擁有足夠的資源支援 Athenex Pharma Solutions 的營運,並在此進程期間,完成 APD 客戶訂單 紐約布法羅, May 15, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ ...
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ...
Athenex has also reached an agreement with its secured lenders, subject to court approval,for the consensual use of cash collateral, whichwill enable the Company to, among other things, satisfy certain obligations to its vendors for authorized goods received and services rendered after .
成立20年:马化腾投资的Biotech公司宣布破产 5月15日,纳斯达克上市的 Biotech 公司 Athenex 宣布破产,同时宣布其名下 ...
Athenex的研发管线以小分子药物为主,其中最为重要的是新一代口服紫杉醇Oraxol,最早由韩国韩美公司开发,2011年,Athenex以750万美元首付款获得了Oraxol的全球开发权。临床应用超过20年的紫杉醇是癌症治疗的重要药物,在多个类型的癌症治疗中属于一线药物,2021 ...